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Chronic Myelomonocytic Leukaemia
A Case Report
E. P. GETAZ.
SUMMARY
A case of chronic myelomonocytic leukaemia and its
therapy are reported, and the response to the new agfilnt,
VP 16-213, is indicated.
S. A/I'. med. J .. 51, 852 (1977).
Since 1913, when acute monocytic leukaemia was des·
cribed by Reschad and Schilling-Torgau,' the entity has
become well accepted by haematologists, and the existence
of a subacute or chronic form is now also accepted. In
the majority of cases there appears to be a well-defined
preleukaemic phase of refractory megaloblastic anaemia.
or persistent monocytosis, or both.
The intravenous epipodophyllotoxin, VP 16-213, has
been u ed in the treatment of myelomonocytic leukaemia
with encouraging results, and it seems that this agent i
particularly effective against cells of the monocytoid
series.'
It is the purpose of this paper to record a patient with
chronic myelomonocytic leukaemia, and to document his
favourable response to treatment with VP 16-213 as the
only form of therapy.
CASE REPORT
A 67-year·old White man presented in February 1975 with
symptoms of anaemia of some 6 months' duration. and
angina pectoris precipitated by his anaemia.
Examination revealed that he had anaemia and a soft
ejection systolic murmur. that the haemoglobin concen-
tration was 6 g/lOO ml with a mean corpuscular volume of
119 p.m', and that there was electrocardiographic evidence
of ischaemic heart disease. Bone marrow aspirate and
trephine biopsy showed granulocytic hyperplasia with an
increase in monocytes and promonocytes. There was also
megaloblastic change in the marrow. Serum B" and folic
acid levels were normal. The patient was given a blood
transfusion and was followed up. He was given no specific
therapy, but required frequent transfusions with packed
red cells.
A repeat bone marrow examination 6 months later in
August showed an elevated monocyte count, and the
cells were positive for alpha· naphthyl acetate esterase.
Serum muramidase was 900 mg/ml and urine mura·
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midase 800 mg/m!. The patient continued to receive
regular transfusions. A splenectomy in September 1975
showed the splenic cords to be widened and infiltrated
with mononuclear cells with indented nuclei. In December
1975 administration of intravenous VP 16·213 began with
a dose of 60 mg/m' body surface for 5 day. This led to
an immediate fall in the white cell count from 250DO/p.1
to 6700/p.!. accompanied by a fall in the absolute mono-
cyte count. The relative monocytosis remained. while
serum and urine muramidase fell rapidly to norma! levels.
Since April 1976 he has been treated with oral VP 16-213
in doses of 120 mg/m' body surface daily for 5 days. The
rest periods between treatment have been extended from
2 to 5 weeks. He has remained well, but requires inter-
mittent transfusion. Withdrawal of the VP 16-213 therapy
leads to a prompt rise in the monocyte count and a drop
in the haemoglobin value. His platelet count has always
remained within normal limits. His marrow bla t count
has varied between 7% and 13%. Blasts have not been
observed in the peripheral blood. Hi only untoward
symptom has been a partial loss of hair.
DISCUSSION
There i considerable variation in the nomenclature of
cases such as this, and they have been variously called
preleukaemia,' subacute myelomonocytic leukaemia:
chronic myelomonocytic leukaemia; smouldering acute
leukaemia' and chronic monocytic leukaemia.7 It seems
that this illness represents part of a pectrum with pre·
leukaemic monocytosis at one end, and frank acute mono·
cytic leukaemia at the other. In Saarni and Linman's'
series of 34 patients with preleukaemia, 10 had an absolute
monocytosis during their illness. A further 5 patients had
a relative monocytosis from 9% to 40%. Saarni and
Linman' concluded that monocytosis is a common and
important preleukaemic manifestation, although none of
the marrow specimens was involved by the monocytosis.
ine of the 34 patients had 'a slight increase' in blasts.
Sinn and Dicks reviewed 14 cases of chronic mono·
cytic leukaemia and added 8 of their own. For inclusion
in their series, it was required that patients should have
had the disease for longer than 1 year, or that there
should have been no evidence of acute leukaemia in the
marrow at the time of diagnosis. They also included in
their series those in whom the disease was of less than
I year's duration, a!1d in whom there were never any.
haematological changes of acute leukaemia in blood or
marrow, and in whom death appeared to occur pre-
maturely as a result of econdary complications such as
infection. Many of their patients had lymphadenopathy.
and/or buccal ulceration and gingival hypertrophy. Only
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3 of the patients were les than 40 years of age. and the
length of survival was between 12 and 43 month. Pearson
and Diamond' have described a case in a child. Their
first patient, however, appears to have had an acute
myelomonocytic leukaemia with a remittent course. Their
second patient was more like those reviewed by Sinn and
Dick," in spite of the finding of peripheral blasts early in
the our e of the di ease; hi marrow spe imen repeatedly
failed to demonstrate malignant change.
In only 3 of the patients reviewed by Sinn and Dick'
was there an appreciable monocytosis over an extended
period of time. Of the 22 patients with chronic monocytic
leukaemia, 9 seemed to be preleukaemic and 8 others had
aleukaemic leukaemia. In most of the patients, leuco-
cytosis and monocytosis typical of acute leukaemia were
noted during the terminal period. In a few. leucopenia
persisted until death. Seligsohn and Ramot' have described
a patient who survived for 8 years. However, 7 month
of this course were preleukaemic and 20 months were
leukaemic.
The French-American-British (FAB) Co-operative
Group'O has recently classified the leukaemias, and recog-
nizes chronic myelomonocytic leukaemia. The monocytic
count is at some stage of the disease higher than 1 x 109 /1.
and the monocytes often appear atypical. The absolute
neutrophil count is variable. Blasts and promonocytes are
rarely present, and the neutrophils may show the same
abnormalities as in refractory anaemia with excess of
blasts. The bone marrow is hypercellular, and usually
shows an increase of up to 30% in myeloblasts and pro-
myelocytes. There is also an increase in promonocytes and
monocytes, but cytochemical staining may be necessary
for identification. Serum lysozyme concentrations are
raised in chronic myelomonocytic leukaemia. but not in
refractory anaemia with excess of blasts.
CONCLUSION
There is clearly no uniformity of opinion about what has
been described as preleukaemia, subacute myelomonocytic.
chronic myelomonocytic. smouldering subacute leukaemia.
and chronic monocytic leukaemia. We would suggest that
the term 'preleukaemia' be re tricted to those patients
with an unexplained monocytosi who ubsequently
appear to develop acute leukaemia. but in whom there
were no signs of leukaemia at diagnosis. In view of the
fact that there is usually an increase in marrow myelo-
blasts in tho e patients with a peripheral blood and
marrow monocyto i. their condition should be termed
chroni myelomonocytic leukaemia. a ugge ted by the
French·American- British Co-operati e Group.
Saarni and Linman' concluded that the preleukaemic
syndrome should not be treated until there is evidence of
haematological malignancy since it may in rare in tances
extend for up to 20 year. In other patient. the condi-
tion of the bone marrow may appear to be more malig-
nant than the peripheral blood would indicate. but they
may have a prolonged survival. ome patients have an
acute terminal phase which re emble myelomonocytic
leukaemia.
Geary eT al.' have felt that these patients are probably
best managed without intensive therapy. In view of this.
we have treated our patient with VP 16-213 with good
results. We have not made any attempt to render his
marrow hypoplastic. Withdrawal of the VP 16-213 lead
to an increase in monocytes. elevation of serum and urine
lysozyme. and an excessive fall in the haemoglobin value.
The only untoward effect we have observed has been a
partial loss of hair. We feel that oral VP 16-213 may be
the drug of choice in the therapy of this condition.
We should like to expre s our thanks to Dr P. Goodson
of Sandoz (Ply) Lld for making VP 16-213 available to us.
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